ADDITIONAL TESTING
Additional Testing
We have created a platform for the development of new tests to help researchers commercialize their interests.
Tempus is partnering with researchers to bring their predictive diagnostic tests to the clinic. We can leverage our molecular and clinical data, CAP/CLIA lab, and clinician network to create algorithms developed in the research setting to help treat cancer patients.
These tests can predict which patients are at higher risk, and therefore might benefit from adjuvant therapy, as well as other endpoints that can positively impact a patient’s journey.
HRD TEST
Tempus HRD is a laboratory-developed test to predict the probability of a patient’s cancer having a phenotype characterized by the inability to repair DNA breaks via the homologous recombination repair (HRR) pathway, known as homologous recombination deficiency (HRD). It is available as an additional test for patients who are tested with Tempus xT.
For ovarian and breast cancer where DNA-based methods of HRD detection are common or under investigation, Tempus HRD provides a result based on DNA genome-wide loss of heterozygosity (GWLOH) or evidence of biallelic BRCA1 or BRCA2 loss. For patients with other cancers, Tempus HRD provides an HRD score based on whole transcriptome RNA expression.
The Tempus HRD advantages:
- No additional tissue required – HRD can be ordered as an add-on with any Tempus|xT test, without additional tissue samples.
- A more complete patient view in one test – Gain additional insight into a patient’s tumor molecular phenotype on top of the genomic profiling results assessed by xT.
TO TEST
The Tempus Tumor Origin (TO) test uses information from analysis of nucleic acids by next-generation sequencing (NGS) performed as part of a separately-ordered Tempus|xT test. The Tempus TO test was built using a large internal database of annotated tumor molecular data. The TO test uses tumor RNA expression results to indicate the most likely primary cancer subtype and other potentially likely subtypes of a tumor specimen from 64 possible diagnostic subtypes.
The intended use of the TO test is for cancers of unknown primary (CUPs) and other tumors of uncertain origin and may help clinicians make more informed decisions where other clinical information like imaging and immunohistochemistry results do not provide a definitive diagnosis.
When paired with xT, the TO results may provide insight into the tumor’s diagnosis and site of origin that may be used to guide patient care and clinical trial eligibility.
